Hemogenyx Pharmaceuticals Administers First-in-Human Dose of HG-CT-1 for AML

HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has issued an update.

Hemogenyx Pharmaceuticals has announced the first administration of its proprietary CAR-T cell therapy, HG-CT-1, to treat relapsed or refractory acute myeloid leukemia in adults. This milestone represents significant progress in their clinical development program, aiming to provide a life-saving treatment for AML patients with limited options, strengthening the company’s position in the biopharmaceutical industry.

More about HemoGenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals is a publicly traded company headquartered in London with subsidiaries in New York City. It is a clinical-stage biopharmaceutical group focused on developing new medicines and treatments for blood and autoimmune diseases, aiming to expand the reach of bone marrow transplantation for otherwise incurable life-threatening diseases. The company is developing multiple product candidates and utilizes a platform technology for novel product development.

YTD Price Performance: -21.60%

Average Trading Volume: 19,569

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £11.44M

For an in-depth examination of HEMO stock, go to TipRanks’ Stock Analysis page.